Étiquette : Inflammation

Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder, Matthew N. Hill et al., 2018

Integrating Endocannabinoid Signaling and Cannabinoids into the Biology and Treatment of Posttraumatic Stress Disorder Matthew N. Hill, Patrizia Campolongo, Rachel Yehuda and Sachin Pate Neuropsychopharmacology REVIEWS, 2018, 43, 80–102. doi : 10.1038/npp.2017.162   Exposure to stress is an undeniable, but in most cases surmountable, part of life. However, in certain individuals, exposure to severe or cumulative stressors can lead to an array of pathological conditions including posttraumatic stress disorder (PTSD), characterized by debilitating trauma-related intrusive thoughts, avoidance behaviors, hyperarousal, as well as depressed mood and anxiety. In the context of the rapidly changing political and legal landscape surrounding use of cannabis products in the USA, [...]

Lire la suite

La maladie d’Alzheimer et le cannabis médical, Kalapa Clinic, 24/09/2020

La maladie d’Alzheimer et le cannabis médical Kalapa Clinic, Barcelone, Espagne By Alexandra|24,09, 2020   La maladie d’Alzheimer neurodégénérative est la forme la plus courante de démence, qui survient généralement chez les personnes âgées de plus de 65 ans. Environ 24 millions de personnes dans le monde souffrent de cette maladie, qui porte le nom du médecin Alois Alzheimer. Il a décrit la maladie pour la première fois en 1906. La maladie d’Alzheimer : Que se passe-t-il dans le cerveau? Chez les patients atteints de la maladie d’Alzheimer, les cellules nerveuses du cerveau meurent progressivement, ce qui entraîne un rétrécissement du cerveau pouvant aller jusqu’à 20 [...]

Lire la suite

How Cannabis-Based Therapeutics Could Help Fight COVID Inflammation, Liz Scherer, 2020

How Cannabis-Based Therapeutics Could Help Fight COVID Inflammation Liz Scherer Medscape.com, November 03, 2020   Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Plagued by false starts, a few dashed hopes, but with perhaps a glimmer of light on the horizon, the race to find an effective treatment for COVID-19 continues. At last count, more than 300 treatments and 200 vaccines were in preclinical or clinical development (not to mention the numerous existing agents that are being evaluated for repurposing). There is also a renewed interest in cannabinoid therapeutics — in particular, the nonpsychoactive agent cannabidiol (CBD) and the prospect of [...]

Lire la suite

FDA Approves Clinical Trials for Cannabinoid Drug Designed to Reduce COVID Lung Inflammation, Ralph Ellis, 2020

FDA Approves Clinical Trials for Cannabinoid Drug Designed to Reduce COVID Lung Inflammation Ralph Ellis Medscape, August 21, 2020 The US Food and Drug Administration has approved phase one clinical trials for a synthetic cannabinoid drug designed to treat acute respiratory distress syndrome (ARDS), a life-threatening lung condition which may occur in severe cases of the novel coronavirus, Forbes reported. ARDS can be triggered by over-creation of cytokines, proteins which tell the body to produce more inflammation, Forbes said. The drug going to clinical trials, ARDS-003, would “dampen the cytokine release" and prevent development of ARDS, Tetra Bio-Pharma company CEO and chief regulatory officer Guy Chamberland, MD, [...]

Lire la suite

Infection VIH et cannabinoides. Etat des lieux et pistes en recherche clinique, Roland Tubiana et Fabienne Caby, RESPADD – GRECC, 2019

Infection VIH et cannabinoides. Etat des lieux et pistes en recherche clinique Roland Tubiana et Fabienne Caby, 24e Rencontres du RESPADD - GRECC, "Usages Cliniques des Cannabinoïdes" 21 juin 2019   (...) Inflammation/ Activation immune et CB Chez les PVVIH traités efficacement, la consommation de CB a été associée: – À des niveaux moins élevés de marqueurs d’inflammation (L B TNF-α+ )/ activation immune (L TCD4+ et CD8+ HLA-DR+CD38+) – A une décroissance plus rapide du niveau d’ADN proviralVIH Mécanismes sous jacents CB (Cannabis Sativa) : > 60 cannabinoides, > 200 non cannabinoides • Cannabinoides: Composant capables d’activer la proteine G couplée aux récepteurs CB1 ou CB2 • Les 2 plus étudiés: Δ9-THC [...]

Lire la suite

Activation of CB1R Promotes Lipopolysaccharide-Induced IL-10 Secretion by Monocytic Myeloid-Derived Suppressive Cells and Reduces Acute Inflammation and Organ Injury, Jérémie Joffre et al., 2020,

Activation of CB1R Promotes Lipopolysaccharide-Induced IL-10 Secretion by Monocytic Myeloid-Derived Suppressive Cells and Reduces Acute Inflammation and Organ Injury Jérémie Joffre, Che-Chung Yeh, Erika Wong, Mayuri Thete, Fengyun Xu, Ivana Zlatanova, Elliot Lloyd, Lester Kobzik, Matthieu Legrand, and Judith Hellman The Journal of Immunology, 2020, 204: 1–20. doi : 10.4049/jimmunol.2000213   Cannabis sativa and its principal components, D9-tetrahydrocannabinol (D9-THC) and cannabidiol, are increasingly being used to treat a variety of medical problems, including inflammatory conditions. Although studies suggest that the endocannabinoid system has immunomodulatory properties, there remains a paucity of information on the effects of cannabinoids on immunity and on outcomes of infection and injury. [...]

Lire la suite

SARS-CoV2 induced respiratory distress : Can cannabinoids be added to anti-viral therapies to reduce lung inflammation ?, Siddappa N. Byrareddy, Mahesh Mohan, 2020

SARS-CoV2 induced respiratory distress : Can cannabinoids be added to anti-viral therapies to reduce lung inflammation ? Siddappa N. Byrareddy, Mahesh Mohan Brain, Behavior, and Immunity, 2020, 1-2. doi : 10.1016/j.bbi.2020.04.079   Keywords : SARS-CoV2, Rhesus macaque, Cannabinoids, Inflammation, Cytokine, Lung   Coronavirus disease-2019 (COVID-19), caused by Severe Acute Respiratory Syndrome coronoavirus-2 (SARS-CoV2) has emerged as a global pandemic, which was first reported in Wuhan, China. Recent reports have suggested that acute infection is associated with a cytokine superstorm, which contributes to the symptoms of fever, cough, muscle pain and in severe cases bilateral interstitial pneumonia characterized by ground glass opacity and focal chest infiltrates that can [...]

Lire la suite

Cannabinol inhibits proliferation and induces cell cycle arrest and apoptosis in glioblastoma, hepatocellular carcinoma and breast cancer cells, Nuanying Zhong, 2020

Cannabinol inhibits proliferation and induces cell cycle arrest and apoptosis in glioblastoma, hepatocellular carcinoma and breast cancer cells Nuanying ZHONG, Thesis, Master of Science in Biological Sciences Faculty of Arts and Science, Department of Biological Sciences, University of Lethbridge Research Repository, Canada 2020 https://hdl.handle.net/10133/5697   ABSTRACT Cannabis sativa is an agriculturally and medicinally plant with many pharmaceutical properties. Cancer is a deadly disease; it is estimated that it will cause over 80 thousand deaths in 2019 in Canada. Although numerous studies have demonstrated that cannabinoids have anti-tumorous properties in various cancers, the anti-malignant activities of cannabinol (CBN) on carcinogenesis and underlying mechanisms remain largely unknown. In this study, we [...]

Lire la suite

CBD Reverts the Mesenchymal Invasive Phenotype of Breast Cancer Cells Induced by the Inflammatory Cytokine IL-1, Lázaro García-Morales et al., 2020

CBD Reverts the Mesenchymal Invasive Phenotype of Breast Cancer Cells Induced by the Inflammatory Cytokine IL-1 Lázaro García-Morales, Aída M Castillo, José Tapia Ramírez, Horacio Zamudio-Meza, Ma del Carmen Domínguez-Robles and Isaura Meza International Journal of Molecular Science, 2020, 21, 2429 doi : 10.3390/ijms21072429   Abstract : Cannabidiol (CBD) has been used to treat a variety of cancers and inflammatory conditions with controversial results. In previous work, we have shown that breast cancer MCF-7 cells, selected by their response to inflammatory IL-1 cytokine, acquire a malignant phenotype (6D cells) through an epithelial mesenchymal transition (EMT).We evaluated CBD as a potential inhibitor of this transition and inducer of [...]

Lire la suite

Immune Responses Regulated by Cannabidiol, James M. Nichols and Barbara L.F. Kaplan, 2019

Immune Responses Regulated by Cannabidiol James M. Nichols and Barbara L.F. Kaplan Cannabis and Cannabinoid Research, 2019, Volume X, Number X Doi : 10.1089/can.2018.0073   Abstract Introduction : Cannabidiol (CBD) as Epidiolex (GW Pharmaceuticals) was recently approved by the U.S. Food and Drug Administration (FDA) to treat rare forms of epilepsy in patients 2 years of age and older. Together with the increased societal acceptance of recreational cannabis and CBD oil for putative medical use in many states, the exposure to CBD is increasing, even though all of its biological effects are not understood. Once such example is the ability of CBD to be anti-inflammatory and [...]

Lire la suite